Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ACP1 | P24666 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | IKBKB | O14920 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1440960 | 0.78 | CACNA1B (0.49) | LMNAALDH1A1ACP1TACR1AKR1B1 | |
| SCHEMBL1441225 | 0.78 | LMNA (0.46) | LMNAALDH1A1ACP1TACR1AKR1B1 | |
| SCHEMBL1441236 | 0.68 | LMNA (0.52) | LMNAALDH1A1ACP1TACR1MAPT | |
| SCHEMBL14263848 | 0.67 | ALDH1A1 (0.65) | LMNAALDH1A1ACP1TACR1KMT2A | |
| SCHEMBL1441276 | 0.66 | SMN1; SMN2 (0.61) | LMNAALDH1A1ACP1TACR1AKR1B1 | |
| SCHEMBL8218118 | 0.64 | ALDH1A1 (0.51) | LMNAALDH1A1ACP1TACR1MAPT | |
| SCHEMBL16628091 | 0.64 | LMNA (0.71) | LMNAALDH1A1ACP1TACR1MEN1 | |
| SCHEMBL263685 | 0.64 | LMNA (0.65) | LMNAALDH1A1ACP1TACR1MAPT | |
| SCHEMBL10750113 | 0.64 | LMNA (0.65) | LMNAALDH1A1ACP1TACR1MAPT | |
| SCHEMBL11738143 | 0.63 | LMNA (0.59) | LMNAALDH1A1ACP1TACR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220603-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | claimed |
| EP-2473488-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | Zalicus Pharmaceuticals Ltd. (CA) | 2012-07-11 | — | — | EP | claimed |
| WO-2011026241-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | ZALICUS PHARMACEUTICALS LTD. (CA) | 2011-03-10 | — | — | WO | claimed |
| US-20120220603-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| US-20120220603-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| EP-2473488-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | Zalicus Pharmaceuticals Ltd. (CA) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011026241-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | ZALICUS PHARMACEUTICALS LTD. (CA) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011026241-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | ZALICUS PHARMACEUTICALS LTD. (CA) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220603-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | CACNA1B, SCN1A, CACNA1I | LMNA 1500/4885ALDH1A1 1017/4885ACP1 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.